Comparison of two different methods for measuring anti-mullerian hormone in a clinical series.

BACKGROUND: Anti Mullerian hormone (AMH) has previously been measured using a manual method, but a fully automated assay from Roche Diagnostics was recently introduced. The aim of this study was to compare the results from the AMH gen II ELISA and Elecsys Cobas AMH methods in a clinical setting to evaluate whether the assays achieve the goals of analytical performance. A prospective observational study with 23 women seeking laparoscopic sterilization was conducted. Blood samples were collected preoperatively as well as 1 week and 1, 3 and 6 months postoperatively; they were evaluated with the AMH gen II ELISA and Elecsys Cobas AMH methods. The assays were validated according to the optimal performance of biochemical assays: CV Analytical < 0.25* CV Within Biological Variation. FINDINGS: We found a good correlation between the two methods; there was a bias of approximately 32 %. The total within-person biological variability ranged from approximately 21 to 32 %. The analytical variability of the AMH gen II ELISA and Elecsys Cobas methods ranged from 5.5 to 10.3 % and 2.8 to 3.3 %, respectively. Applying the goals for optimal assay performance, the Elecsys Cobas method achieved optimal performance throughout the measuring range, whereas the AMH Gen II only achieved optimal performance in the high end of the measuring range. Furthermore, the Elecsys Cobas assay had a low limit of quantitation of 0.5 pmol/l compared to 3.0 pmol/l for the AMH gen II ELISA. CONCLUSIONS: In the clinical setting, the Elecsys Cobas AMH assay performs well according to the optimal standard for biochemical assays.

The association between gender, stage and prognosis in bladder cancer patients undergoing radical cystectomy.

OBJECTIVE: The incidence of bladder cancer is three times as high in men compared to women. Moreover, women are generally diagnosed with a more severe tumor stage and have poorer prognosis. This study aimed to examine the association between gender, stage, and prognosis among a subgroup of bladder cancer patients treated with radical cystectomy. PATIENTS AND METHODS: A total of 460 patients (131 women, 329 men) with bladder cancer undergoing radical cystectomy at Aarhus University Hospital in 2015-2018 were retrospectively selected for this study and followed until 2021 at the latest. Correlations between gender, patient and tumor characteristics and oncological outcomes were analyzed by the Chi-squared test. By the use of multiple linear regression, we adjusted for age, comorbidity and the proportion of organ-confined and non-organ-confined disease at diagnosis. RESULTS: Female patients were found to be younger and less comorbid than male patients. A higher proportion of patients with muscle-invasive bladder cancer and non-organ-confined disease at the time of cystectomy was observed among female patients. Recurrence of cancer occurred 3.4 (0.1-6.7) months earlier in female patients, and they had a 47% higher cancer-specific mortality (RR = 1.47 (1.04-2.1)) compared to male patients. In the adjusted analysis, the association of an earlier recurrence in female patients remained. CONCLUSION: This study verifies that gender disparities exist among bladder cancer patients, even after adjusting for age, comorbidity and for the proportion of organ-confined and non-organ-confined disease at cystectomy. Further investigations are required to investigate the etiology of this observed difference between sexes.

The Inequality of Females in Bladder Cancer.

Urinary bladder cancer is worldwide one of the most diagnosed and costly types of cancer. One puzzle in the bladder cancer diagnosis is the disproportional relationship between genders. Males are more likely to be diagnosed with bladder cancer whereas females typically are diagnosed with more adverse disease and worse prognosis, which has led to speculation of the potential role of sex hormones and their receptors in this disease. Estrogen receptors are present in the human bladder, and their role in bladder cancer oncogenesis is increasingly becoming a focus for researchers around the world. This mini-review aims to give a brief overview of the status of female bladder cancer, and to which extend the sex hormones receptors play a role in this. A literature search was performed and included all female original studies on bladder cancer and hormone receptors. Estrogen-receptor alpha seems to be anti-oncogenic whereas estrogen-receptor beta is exhibiting its function pro-oncogenic. The receptor functions may be exercised through mRNA transcriptions and enzymes. Epidemiological studies indicate a potential increase in incidence of bladder cancer for females with earlier age at menopause, and clinical trials are investigating Tamoxifen as a potential treatment in bladder cancer. Increasing evidence supports the theory of bladder cancer development and progression as being partly hormone-dependent. This can lead to a change in conceptual background of bladder cancer etiology and development in the future. Further studies are required to more precise map the use of anti-hormonal drugs in the treatment of this cancer.

[Foreign objects in the urethra].

Foreign objects in the urethra are rare. Most cases are often caused by self-mutilating behaviour, in which the patient inserts an object into the urethra. Usually this is performed in a sexual context, and many different objects have been used. This case report presents a patient who used a 4 cm bullet-looking metal object for sexual pleasure. Cystoscopy revealed an object deep in the urethra, penetrating through the urethral mucosa. The object was removed endoscopically. At follow-up the patient experienced no sequelae, although infections, urethral stricture or fistula may occur in these cases.

[Anti-Müllerian hormone is a clinical useful measure of the ovarian reserve]. / Antimüllersk hormon er et klinisk anvendeligt mål for ovariereserve

Anti-Müllerian hormone (AMH) is produced by the growing follicles in the ovaries. The number of follicles in this pool is proportional to the number of primordial follicles in the resting pool (the "ovarian reserve"), thus AMH is believed to be a surrogate marker of the ovarian reserve. AMH is a useful adjunct in the evaluation of a woman's "reproductive age", being an important parameter in counselling for reproduction. AMH is also used in pretreatment evaluation of infertile patients guiding proper hormone stimulation. Furthermore, AMH can be used as a tumour marker for granulose cell tumours.